Stryker Co. (NYSE:SYK) Stock Position Raised by ST Germain D J Co. Inc.

ST Germain D J Co. Inc. lifted its position in Stryker Co. (NYSE:SYK) by 14.5% in the 4th quarter, Holdings Channel reports. The fund owned 2,362 shares of the medical technology company’s stock after buying an additional 300 shares during the period. ST Germain D J Co. Inc.’s holdings in Stryker were worth $850,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Rempart Asset Management Inc. lifted its position in Stryker by 5.0% in the 4th quarter. Rempart Asset Management Inc. now owns 49,496 shares of the medical technology company’s stock worth $17,821,000 after buying an additional 2,351 shares in the last quarter. Bath Savings Trust Co lifted its position in Stryker by 0.7% in the 4th quarter. Bath Savings Trust Co now owns 113,412 shares of the medical technology company’s stock worth $40,834,000 after buying an additional 823 shares in the last quarter. Regent Peak Wealth Advisors LLC purchased a new stake in Stryker in the 4th quarter worth approximately $204,000. CWA Asset Management Group LLC lifted its position in Stryker by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 3,854 shares of the medical technology company’s stock worth $1,388,000 after buying an additional 131 shares in the last quarter. Finally, Nordea Investment Management AB lifted its position in Stryker by 15.8% in the 4th quarter. Nordea Investment Management AB now owns 971,735 shares of the medical technology company’s stock worth $350,485,000 after buying an additional 132,513 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 target price on shares of Stryker in a research report on Tuesday. Piper Sandler reiterated an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. BTIG Research increased their price target on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Barclays increased their price target on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Finally, UBS Group increased their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Stryker Stock Performance

NYSE SYK opened at $366.04 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a market capitalization of $139.54 billion, a price-to-earnings ratio of 39.23, a P/E/G ratio of 2.82 and a beta of 0.95. The company’s fifty day moving average is $375.40 and its two-hundred day moving average is $357.70. Stryker Co. has a 52-week low of $306.10 and a 52-week high of $398.20.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the business posted $2.46 EPS. Equities research analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.92%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.